Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Giannoula Klement"'
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 3, p e0226883 (2020)
PLoS ONE, Vol 15, Iss 3, p e0226883 (2020)
We analyzed protein expression data for Lupus patients, which have been obtained from publicly available databases. A combination of systems biology and statistical thermodynamics approaches was used to extract topological properties of the associate
Publikováno v:
Journal of Pediatric Hematology/Oncology. 38:563-569
Despite the advances in oncology, the survival of children with Ewing Sarcoma metastatic at diagnosis continues to be 27% 3-year event-free survival and 34% 3-year overall survival. In other words, 7 of 10 children die within 3 years of their initial
Publikováno v:
Lim, Yeun Jina; Rosmarin, David; Klement, Giannoula; & Au, Shiu-chung. (2017). Klippel-Trenauney syndrome with axillary hyperhidrosis. Dermatology Online Journal, 23(6). Retrieved from: http://www.escholarship.org/uc/item/9448f90f
Klippel-Trenaunay syndrome (KTS) is a rare, clinically variable congenital disorder involving capillary malformations, soft tissue or bone hypertrophy, and venous malformations or varicose veins. We report a 28-year-old man who presented with a hyper
Publikováno v:
Oncotarget
// Edward. A. Rietman 1 , Jacob G. Scott 2, 3 , Jack A. Tuszynski 4, 5 , Giannoula Lakka Klement 6, 7, 8 1 BINDS lab, College of Information and Computer Sciences, University of Massachusetts Amherst, Amherst, MA, USA 2 Wolfson Center for Mathematica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c17b80bdc2eeab7abdbde51a88e9119d
http://hdl.handle.net/11583/2707380
http://hdl.handle.net/11583/2707380
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 12, p e0166655 (2016)
PLoS
PLoS ONE, Vol 11, Iss 12, p e0166655 (2016)
PLoS
Both normal wound healing and tumor angiogenesis are mitigated by the sequential, carefully orchestrated release of growth stimulators and inhibitors. These regulators are released from platelet clots formed at the sites of activated endothelium in a
Publikováno v:
Cancer Research. 73:2949-2954
Metronomic chemotherapy, the delivery of doses in a low, regular manner so as to avoid toxic side effects, was introduced over 12 years ago in the face of substantial clinical and preclinical evidence supporting its tumor-suppressive capability. It c
Thermodynamics is an important driving factor for chemical processes and for life. Earlier work has shown that each cancer has its own molecular signaling network that supports its life cycle and that different cancers have different thermodynamic en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85614bec4bd53e029ab2ca26afab936a
https://europepmc.org/articles/PMC4942417/
https://europepmc.org/articles/PMC4942417/
Autor:
Giannoula Klement
Publikováno v:
Science Translational Medicine. 8
For the past 60 years, the goal of conventional cancer therapies has been the eradication of every cancer cell. To this end, patients are subjected to the highest possible doses of radiation and chemotherapy as well as radical surgeries. In the rare
Autor:
Ondrej Slaby, Ali Hashemi, Paolo Carmassi, Csongor Kiss, Leos Kren, Edward A. Rietman, Giannoula Klement, A Kolenova, Jiri Tuma, Irene Slavc, Peter Múdry, Tina Roffidal, Nicolas André, Knarik Arkun, Gabor G. Kovacs, Koen Norga, Dobrin Konstantinov, Henk van den Berg, Jarmila Skotáková, Dalibor Valík, Christos Klement, Pavel Mazánek, Jaroslav Sterba
Publikováno v:
Oncotarget
Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1201639880c816892ac1e9731ed96c96
Autor:
Michael Dabrowski, Olga Babich, Olof Larsson, Per-Eric Lund, Giannoula Klement, Zara A. Sands, Asa Malmberg, Lars Sandberg
Publikováno v:
Combinatorial Chemistry & High Throughput Screening. 15:713-720
Congenital Insensitivity to Pain (CIP) is a loss of function mutation resulting in a truncated NaV1.7 protein, suggesting a pivotal role in pain signaling and rendering it an important pharmaceutical target for multiple pain conditions. The structura